Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : FP-008
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fapon Biopharma Gets FDA IND Approval for FP008 Immunotherapy for Solid Tumors
Details : FP008 is a novel anti-PD-1×IL-10M fusion protein, designed to address the unmet need in patients with solid tumors refractory to anti-PD-1 therapy.
Product Name : FP008
Product Type : Protein
Upfront Cash : Inapplicable
February 28, 2025
Lead Product(s) : FP-008
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : FP002
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fapon Biopharma's Anti-CD47 Antibody FP002 Earns IND Approval from FDA
Details : FP002 is a humanized anti-CD47 IgG4 monoclonal antibody which binds and inhibits CD47 protein on the surface of tumor cells, triggering the recognition and elimination of cancer cells by the innate immunity.
Product Name : FP002
Product Type : Antibody
Upfront Cash : Inapplicable
February 22, 2023
Lead Product(s) : FP002
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
